We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) reported a loss of 69 cents per share for the second quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of 72 cents but wider than the year-ago loss of 45 cents.
Quarterly revenues were down 42% year over year to $28.3 million during the quarter. However, revenues beat the Zacks Consensus Estimate of $26.42 million. In the year-ago period, the company had recorded milestone payment of $25 million from its partner, Bristol-Myers (BMY - Free Report) related to initiation of the registrational study of Nektar’s bempegaldesleukin plus Bristol-Myers’ Opdivo in adjuvant melanoma. Such milestone payment was absent during the reported quarter.
Nektar’s shares were up 1.4% in after-hours trading on Aug 5 following robust quarterly results. Shares of the company have declined 6.7% so far this year compared with the industry’s decrease of 11.1%.
Image Source: Zacks Investment Research
Quarter in Detail
Nektar’s top line comprises product sales, royalty revenues, non-cash royalty revenues along with license, collaboration and other revenues.
In the second quarter, product sales increased 43% from the year-ago period to $7.8 million. Non-cash royalty revenues were $20.5 million in the quarter compared with $7.7 million in the year-ago quarter.
License, collaboration and other revenues were $28,000 in the quarter compared with $26.3 million in the year-ago quarter. The year-ago period included the Bristol-Myers’ milestone payment.
Research and development (R&D) expenses increased 5.1% to $101.3 million. General and administrative (G&A) expenses were up 21.4% year over year to $29.6 million in the reported quarter. The increase in G&A expenses was led by costs to support pre-commercialization activities related to bempegaldesleukin.
Pipeline Update
Nektar remains on track with the development of its lead pipeline candidate, bempegaldesleukin, as a potential treatment for different oncology indications.
Top-line data from three registrational studies evaluating bempegaldesleukin plus Opdivo in patients with melanoma, renal cell carcinoma and bladder cancer is expected in the first half of 2022. Two other registrational studies are evaluating the combination regimen as potential treatment for urothelial cancer and adjuvant melanoma.
Data from the phase I/II study — PROPEL — evaluating bempegaldesleukin in combination with Merck’s (MRK - Free Report) Keytruda for treating metastatic non-small cell lung cancer is expected later this year. A phase II/III study is evaluating the combination regimen as first-line treatment for metastatic or unresectable recurrent squamous cell carcinoma of the head and neck in patients whose tumors express PD-L1.
Apart from bempegaldesleukin, Nektar has two other key pipeline candidates — NKTR-255 and NKTR-358. The company’s partner, Eli Lilly (LLY - Free Report) is evaluating NKTR-358 in several early- to mid-stage studies targeting inflammatory or autoimmune diseases. Nektar is developing NKTR-255 for treating several oncology indications including non-Hodgkin lymphoma, multiple myeloma, head and neck squamous cell carcinoma and colorectal cancer in early-stage studies.
Nektar Therapeutics Price, Consensus and EPS Surprise
Image: Bigstock
Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track
Nektar Therapeutics (NKTR - Free Report) reported a loss of 69 cents per share for the second quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of 72 cents but wider than the year-ago loss of 45 cents.
Quarterly revenues were down 42% year over year to $28.3 million during the quarter. However, revenues beat the Zacks Consensus Estimate of $26.42 million. In the year-ago period, the company had recorded milestone payment of $25 million from its partner, Bristol-Myers (BMY - Free Report) related to initiation of the registrational study of Nektar’s bempegaldesleukin plus Bristol-Myers’ Opdivo in adjuvant melanoma. Such milestone payment was absent during the reported quarter.
Nektar’s shares were up 1.4% in after-hours trading on Aug 5 following robust quarterly results. Shares of the company have declined 6.7% so far this year compared with the industry’s decrease of 11.1%.
Image Source: Zacks Investment Research
Quarter in Detail
Nektar’s top line comprises product sales, royalty revenues, non-cash royalty revenues along with license, collaboration and other revenues.
In the second quarter, product sales increased 43% from the year-ago period to $7.8 million. Non-cash royalty revenues were $20.5 million in the quarter compared with $7.7 million in the year-ago quarter.
License, collaboration and other revenues were $28,000 in the quarter compared with $26.3 million in the year-ago quarter. The year-ago period included the Bristol-Myers’ milestone payment.
Research and development (R&D) expenses increased 5.1% to $101.3 million. General and administrative (G&A) expenses were up 21.4% year over year to $29.6 million in the reported quarter. The increase in G&A expenses was led by costs to support pre-commercialization activities related to bempegaldesleukin.
Pipeline Update
Nektar remains on track with the development of its lead pipeline candidate, bempegaldesleukin, as a potential treatment for different oncology indications.
Top-line data from three registrational studies evaluating bempegaldesleukin plus Opdivo in patients with melanoma, renal cell carcinoma and bladder cancer is expected in the first half of 2022. Two other registrational studies are evaluating the combination regimen as potential treatment for urothelial cancer and adjuvant melanoma.
Data from the phase I/II study — PROPEL — evaluating bempegaldesleukin in combination with Merck’s (MRK - Free Report) Keytruda for treating metastatic non-small cell lung cancer is expected later this year. A phase II/III study is evaluating the combination regimen as first-line treatment for metastatic or unresectable recurrent squamous cell carcinoma of the head and neck in patients whose tumors express PD-L1.
Apart from bempegaldesleukin, Nektar has two other key pipeline candidates — NKTR-255 and NKTR-358. The company’s partner, Eli Lilly (LLY - Free Report) is evaluating NKTR-358 in several early- to mid-stage studies targeting inflammatory or autoimmune diseases. Nektar is developing NKTR-255 for treating several oncology indications including non-Hodgkin lymphoma, multiple myeloma, head and neck squamous cell carcinoma and colorectal cancer in early-stage studies.
Nektar Therapeutics Price, Consensus and EPS Surprise
Nektar Therapeutics price-consensus-eps-surprise-chart | Nektar Therapeutics Quote
Zacks Rank
Nektar currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.